Inventor · disambiguated record
Christopher O'Brien
Also filed as: O'BRIEN CHRISTOPHER · O'BRIEN CHRISTOPHER B · O`BRIEN CHRISTOPHER F
16 granted patents·17 pending applications·92 citations·filing 2003–2025
93Inventor score
Top patents by PatentIndex Score
33 records- 0197US10952997B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Mar 23, 2021·11 cites·26 claims
- 0297US10912771B1Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Feb 9, 2021·11 cites·15 claims
- 0397US10857148B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Dec 8, 2020·9 cites·25 claims
- 0497US10857137B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Dec 8, 2020·11 cites·30 claims
- 0596US11040029B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Jun 22, 2021·6 cites·26 claims
- 0696US10993941B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted May 4, 2021·11 cites·29 claims
- 0795US11311532B2High dosage valbenazine formulation and compositions, methods, and kits related theretoNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Apr 26, 2022·3 cites·32 claims
- 0894US10874648B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2017·Granted Dec 29, 2020·11 cites·4 claims
- 0990US11780911B2Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alphaJANSSEN BIOTECH INC·Filed 2020·Granted Oct 10, 2023·4 cites·42 claims
- 1087US11439629B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Sep 13, 2022·1 cites·32 claims
- 1187US11026931B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted Jun 8, 2021·6 cites·30 claims
- 1280US10961307B2Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibodyJANSSEN BIOTECH INC·Filed 2019·Granted Mar 30, 2021·3 cites·34 claims
- 1380US9815894B2Use of reslizumab to treat moderate to severe eosinophilic asthmaO'BRIEN CHRISTOPHER·Filed 2015·Granted Nov 14, 2017·4 cites·14 claims
- 1477US12258393B2Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alphaJANSSEN BIOTECH INC·Filed 2021·Granted Mar 25, 2025·1 cites·7 claims
- 1572US2024010718A1Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alphaJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1671US2024182557A1Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1769US11654142B2Methods for the administration of certain VMAT2 inhibitorsNEUROCRINE BIOSCIENCES INC·Filed 2020·Granted May 23, 2023·0 cites·15 claims
- 1867US2024294625A1Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1965US2024002494A1Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 2064US2021196702A1Treatment of hyperkinetic movement disordersNEUROCRINE BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2162US2025236664A1Method of treating ulcerative colitis with an antibody to IL-23JANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 2259US2021171622A1Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2359US2020101063A1Treatment of hyperkinetic movement disordersNEUROCRINE BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 2454US2021253690A1Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2553US2008171065A1Methods of Treating Nerve Entrapment SyndromesO'BRIEN CHRISTOPHER·Filed 2008·Application pending·0 cites
- 2653US2021115129A1Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 2752US10577414B2Use of reslizumab to treat moderate to severe eosinophilic asthmaCEPHALON INC·Filed 2017·Granted Mar 3, 2020·0 cites·18 claims
- 2852US2022372129A1Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF AlphaJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2951US2025171530A1Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF AlphaJANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 3049US2003224019A1Methods of treating nerve entrapment syndromesFiled 2003·Application pending·0 cites
- 3147US2017071932A1Treatment of hyperkinetic movement disordersNEUROCRINE BIOSCIENCES INC·Filed 2015·Application pending·0 cites
- 3239US2004062754A1Photopheresis treatment of chronic HCV infectionsFiled 2003·Application pending·0 cites
- 3338US2019015396A1Vmat2 inhibitors for treating neurological diseases or disordersNEUROCRINE BIOSCIENCES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher O'Brien files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →